Bas J. Wouters

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Venetoclax plus hypomethylating agents as a bridge to transplant or donor lymphocyte infusion in relapsed/ refractory acute myeloid leukemia.

Venetoclax plus hypomethylating agents as a bridge to transplant or donor lymphocyte infusion in relapsed/ refractory acute myeloid leukemia.

Journal: Haematologica
Published: May 08, 2025

MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia.

MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia.

Journal: Blood
Published: February 21, 2025

Epigenetic alterations affecting hematopoietic regulatory networks as drivers of mixed myeloid/lymphoid leukemia.

Epigenetic alterations affecting hematopoietic regulatory networks as drivers of mixed myeloid/lymphoid leukemia.

Journal: Nature communications
Published: August 11, 2023

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending Questions.

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending Questions.

Journal: HemaSphere
Published: March 22, 2021

Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML.

Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML.

Journal: Blood
Published: September 28, 2020

BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells.

BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells.

Journal: Blood
Published: June 28, 2019

Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation.

Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation.

Journal: Cancer cell
Published: February 06, 2019

Hitting the target in IDH2 mutant AML.

Hitting the target in IDH2 mutant AML.

Journal: Blood
Published: August 12, 2017

Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations.

Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations.

Journal: The Journal of molecular diagnostics : JMD
Published: January 12, 2017

Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.

Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.

Journal: Cancer discovery
Published: September 15, 2016

Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia.

Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia.

Journal: Blood
Published: July 22, 2015

HAT: a novel statistical approach to discover functional regions in the genome.

HAT: a novel statistical approach to discover functional regions in the genome.

Journal: Methods in molecular biology (Clifton, N.J.)
Published: August 27, 2013
Showing 1-12 of 14

Last Updated: 09/26/2026